Product Description
Emraclidine is an orally available muscarinic M4 Receptor (PAM) being investigated for the treatment of schizophrenia and other forms of psychosis. (Sourced from: https://www.abbvie.com/science/pipeline.html)
Mechanisms of Action: M4 PAM
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: AbbVie
Company Location: Eastern America
Company Founding Year: 2013
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Bulgaria, Hungary, United States
Active Clinical Trial Count: 13
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Psychotic Disorders
Phase 1: Alzheimer Disease|Healthy Volunteers|Kidney Diseases|Other
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05227690 |
CVL-231-2001 | P2 |
Completed |
Psychotic Disorders|Schizophrenia |
2024-08-23 |
2025-09-18 |
Primary Endpoints|Treatments |
|
NCT05644977 |
CVL-231-1006 | P1 |
Completed |
Alzheimer Disease |
2025-04-14 |
2025-05-03 |
Primary Endpoints |
|
NCT05935033 |
CVL-231-SP-1008 | P1 |
Completed |
Other |
2025-02-21 |
2025-03-06 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
2024-511441-19-00 |
CVL-231-2003 | P2 |
Active, not recruiting |
Schizophrenia |
2026-02-28 |
2025-05-02 |
Treatments |
|
NCT05940402 |
CVL-231-SP-1007 | P1 |
Completed |
Kidney Diseases |
2024-12-19 |
2025-03-06 |
||
NCT07145918 |
M25-522 | P2 |
Recruiting |
Schizophrenia |
2028-02-01 |
12% |
2026-02-12 |
|
2022-000581-17 |
2022-000581-17 | P2 |
Completed |
Schizophrenia |
2024-09-11 |
2025-05-06 |
Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
2022-000580-52 |
2022-000580-52 | P2 |
Completed |
Schizophrenia |
2024-08-26 |
2025-05-06 |
Patient Enrollment|Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
NCT05227703 |
CVL-231-2002 | P2 |
Completed |
Schizophrenia |
2024-08-15 |
2024-12-21 |
||
NCT07219030 |
M25-904 | P1 |
Recruiting |
Healthy Volunteers |
2027-03-01 |
88% |
2026-05-13 |
|
NCT07587008 |
M26-506 | P1 |
Completed |
Healthy Volunteers |
2026-07-17 |
50% |
2026-08-15 |
Primary Completion Date|Primary Endpoints|Study Completion Date |
NCT06366243 |
CVL-231-HV-1012 | P1 |
Completed |
Healthy Volunteers |
2024-06-20 |
2024-07-25 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
NCT06301971 |
CVL-231-HV-1011 | P1 |
Completed |
Healthy Volunteers |
2024-04-04 |
2024-05-03 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
12/06/2023 |
News Article |
AbbVie to Acquire Cerevel Therapeutics in Transformative Transaction to Strengthen Neuroscience Pipeline |
|
10/07/2021 |
News Article |
Cerevel Therapeutics Hosts Virtual R&D Event to Review CVL-871 in Dementia-Related Apathy and Provide Update on CVL-231 for the Treatment of Schizophrenia |
|
09/10/2021 |
News Article |
Cerevel Therapeutics to Host Virtual R&D Event on October 7 |
|
06/29/2021 |
News Article |
Cerevel Therapeutics Announces Positive Topline Results for CVL-231 in Phase 1b Clinical Trial in Patients with Schizophrenia |